Oct 20 (Reuters) - BIOSYNEX SA ALBIO.PA :
* H1 CONSOLIDATED NET RESULT EUR 70.5 MILLION VERSUS EUR 6.2
MILLION YEAR AGO
* H1 REVENUE EUR 225.2 EUR VERSUS 44.1 MILLION YEAR AGO
* H1 GROSS OPERATING PROFIT EUR 98.3 MILLION VERSUS EUR 8.6
MILLION YEAR AGO
* AS AN EXTENSION OF THE PRESS RELEASE PUBLISHED ON OCTOBER
14,
BIOSYNEX WILL INTENSIFY ITS EFFORTS TO PENETRATE NEW COUNTRIES
FOR ITS SARS-COV TESTS
* CASH POSITION PROVIDES THE GROUP WITH NECESSARY RESOURCES
TO
ENSURE ITS DEVELOPMENT AND CARRY OUT FUTURE EXTERNAL GROWTH
OPERATIONS
* THE STRONG CASH GENERATION FROM THE LAST 12 MONTHS NOW
GIVES
BIOSYNEX THE MEANS TO FULFILL ITS AMBITIONS IN TERMS OF EXTERNAL
GROWTH
* GROSS FINANCIAL DEBT REACHED €23.0 MILLION AT THE END OF
JUNE
2021 COMPARED TO €15.8 MILLION SIX MONTHS EARLIER
Source text for Eikon: ID:nBw9lzLRba
Further company coverage: ALBIO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))